BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: CD3; HIV env

October 22, 2015 7:00 AM UTC

In vitro studies suggest a dual-affinity re-targeting (DART) antibody against CD3 and HIV env could help treat HIV infection. A DART consisting of two disulfide-linked polypeptide chains corresponding to the variable domains of an anti-CD3 antibody and a broadly neutralizing anti-HIV env antibody bound CD3 and HIV env with Kd values of 6.1 and 15.1 nM, respectively. In co-cultures of human CD8+ T cells and HIV-infected human CD4+ T cells, the anti-CD3/HIV env DART decreased markers of HIV growth compared with a DART targeting CD3 and fluorescein. Next steps include testing the anti-CD3/HIV env DART in animal models of HIV infection...